The US Food and Drug Administration (FDA) has released the first of two new pieces of draft guidance that may eventually enable e-cigarette manufacturers to apply for regulated drug status for their products.  FDA Commissioner Scott Gottlieb, MD, said there is “no greater impact we can...

New safety labeling changes for fluoroquinolone antibiotics, require these medications to carry stronger warnings about potential mental health side effects and the risk of serious blood sugar disturbances. The US Food and Drug Administration (FDA) announced measures to improve labeling consistency...

GlaxoSmithKline’s once-daily triple therapy, the Trelegy Ellipta (fluticasone furoate, umeclidinium, vilanterol), is superior to dual combination therapies in reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) with a history of exacerbations, new research...

The US Food and Drug Administration (FDA) has approved Sunovion’s Lonhala Magnair (glycopyrrolate), making it the first nebulized long-acting muscarinic antagonist (LAMA) treatment in the United States for patients with chronic obstructive pulmonary disease (COPD). It is expected to appear in...